Aptus Pharma Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Aptus Pharma Ltd is ₹ 405 as of 30 Apr 15:30 . The P/E Ratio of Aptus Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Aptus Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Aptus Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The ebitda of Aptus Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The net profit of Aptus Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The Dividend Payout of Aptus Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Aptus Pharma Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Aptus Pharma Ltd or Morepen Laboratories Ltd?

Market cap of Aptus Pharma Ltd is 277 Cr while Market cap of Morepen Laboratories Ltd is 2,269 Cr

What are the key factors driving the stock performance of Aptus Pharma Ltd and Morepen Laboratories Ltd?

The stock performance of Aptus Pharma Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aptus Pharma Ltd and Morepen Laboratories Ltd?

As of May 4, 2026, the Aptus Pharma Ltd stock price is INR ₹405.0. On the other hand, Morepen Laboratories Ltd stock price is INR ₹41.41.

How do dividend payouts of Aptus Pharma Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Aptus Pharma Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.